Tendyne Holdings

About:

Tendyne is a medical device company developing a transcatheter aortic valve implantation system.

Website: http://www.tendyne.com

Twitter/X: tendyne

Top Investors: Apple Tree Partners

Description:

Tendyne Holdings, Inc. is a clinical stage medical device company focused on the development of minimally invasive therapies for the treatment of mitral regurgitation. Mitral regurgitation is a condition that afflicts hundreds of thousands of individuals worldwide every year. Formed in 2010, their first product concept is a transcatheter mitral valve replacement prosthesis for the treatment of mitral regurgitation. The intent is for the valve to be deployed and secured with no disruption to the native mitral annulus while preserving the sub-valvular apparatus. Placement of the valve is intended to be completed transapically in a simple procedure where the implanting physician is able to re-position, remove, and re-deploy their valve throughout the procedure.

Total Funding Amount:

$37.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Rockville, Minnesota, United States

Founded Date:

2010-01-01

Contact Email:

info(AT)tendyne.com

Founders:

Jeff Franco

Number of Employees:

11-50

Last Funding Date:

2014-04-09

IPO Status:

Private

Industries:

© 2025 bioDAO.ai